1
Tarran Jones
David M Hilbert, Tarran Jones, David G Williams: Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Medimmune, Aeres Biomedical, Jones Day, November 9, 2010: US07829086 (17 worldwide citation)

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework r ...


2
Tarran Jones
Tarran Jones, David G Williams: Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. MedImmune, Mueting Raasch & Gebhardt P A, March 4, 2014: US08664363

Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and light chain variable region (“VK”). The FW regions may contain one or more backmutation ...


3
Tarran Jones
David M Hilbert, Tarran Jones, David G Williams: Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Medimmune, July 28, 2011: US20110182887-A1

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework r ...


4
Leslie Sid Johnson: Human-murine chimeric antibodies against respiratory syncytial virus. MedImmune, Elliot M Olstein, October 20, 1998: US05824307 (118 worldwide citation)

This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb1129 and the use thereof for the prevention and/or treatment of RSV infection.


5
William Dall Acqua, Leslie S Johnson, Elizabeth Sally Ward: Molecules with extended half-lives, compositions and uses thereof. MedImmune, Jones Day, August 1, 2006: US07083784 (102 worldwide citation)

The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase ...


6
James F Young, Scott Koenig, Leslie S Johnson: Anti-RSV antibodies. MedImmune, Jones Day, November 16, 2004: US06818216 (53 worldwide citation)

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a ...


7
Ram Kripa, Venkat Raghavan: Antibodies with decreased deamidation profiles. Medimmune, Ram Kripa, Venkat Raghavan, HOLMES SON Michelle, October 9, 2008: WO/2008/121616 (47 worldwide citation)

The present invention relates to antibodies with decreased deamidation profiles, and methods for producing antibodies with decreased deamidation profiles.


8
Leslie S Johnson, John E Adamou: Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS. MedImmune, Elliot M Olstein, Alan J Grant, June 24, 2003: US06582706 (45 worldwide citation)

A vaccine composition is disclosed that comprises polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by


9

10
Matthew David Osborne, Jonathan H Dempsey: Myeloma cell culture in transferrin-free low iron medium. Medimmune, Nixon & Vanderhye P C, January 29, 2013: US08361797 (40 worldwide citation)

The present invention relates to a method for culturing mammalian cells in a culture medium which is transferrin free and which contains no lipophilic or synthetic nitrogen-containing chelators. Also provided is the use of the medium and a process for providing a mammalian product by culturing cells ...